<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Diseases associated with glycosylation precursor biosynthesis" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Glycosylation diseases associated with the enzymes that mediate the biosynthesis of glycosylation precursors are curated in this section (Jaeken &amp; Matthijs 2007, Freeze et al. 2015).
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=5609975 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 5609975</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Jassal, Bijay</Comment>
  <BiopaxRef>ca4</BiopaxRef>
  <BiopaxRef>a59</BiopaxRef>
  <Attribute Key="reactome_id" Value="5609975" />
  <Graphics BoardWidth="719.0" BoardHeight="450.0" />
  <DataNode TextLabel="Defective GALK1&#xA;causes GALCT2" GraphId="b75ad" Type="Pathway">
    <Comment Source="Reactome">Cytosolic galactokinase (GALK1) catalyses the first committed step in the Leloir pathway of galactose metabolism. GALK1 catalyses the phosphorylation of D-galactose (Gal) to form D-galactose 1-phosphate (Gal1P). Defects in GALK1 can cause type II galactosemia (GALCT2; MIM:230200), an autosomal recessive deficiency characterised by congenital cataracts during infancy and presenile cataracts in the adult population. Galactitol accumulation in the lens is the cause of these cataracts (Bosch et al. 2002).</Comment>
    <BiopaxRef>ec6</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="622.5" CenterY="67.5" Width="133.0" Height="83.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5609976" />
  </DataNode>
  <DataNode TextLabel="Defective SRD5A3&#xA;causes SRD5A3-CDG,&#xA;KHRZ" GraphId="a44ea" Type="Pathway">
    <Comment Source="Reactome">Polyprenol reductase (SRD5A3), resident on the endoplasmic reticulum membrane, normally mediates the reduction of the alpha-isoprene unit of polyprenol (pPNOL) to form dolichol (DCHOL) in a NADPH-dependent manner (Cantagrel et al. 2010). DCHOLs are substrates required for the synthesis of the lipid-linked oligosaccharide (LLO) precursor used for N-glycosylation. Defects in SRD5A3 cause congenital disorder of glycosylation 1q (SRD5A3-CDG, CDG1q; MIM:612379), a neurodevelopmental disorder characterised by under-glycosylated serum glycoproteins resulting in nervous system development, psychomotor retardation, hypotonia, coagulation disorders and immunodeficiency (Cantagrel et al. 2010, Kasapkara et al. 2012). Defects in SRD5A3 can also cause Kahrizi syndrome (KHRZ; MIM:612713), a neurodevelopmental disorder characterised by mental retardation, cataracts, holes in eye structures, pathological curvature of the spine, and coarse facial features (Kahrizi et al. 2011).</Comment>
    <BiopaxRef>e11</BiopaxRef>
    <BiopaxRef>bc9</BiopaxRef>
    <BiopaxRef>aa2</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="268.5" CenterY="172.5" Width="155.0" Height="79.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4755579" />
  </DataNode>
  <DataNode TextLabel="Defective GFPT1&#xA;causes CMSTA1" GraphId="c7bd8" Type="Pathway">
    <Comment Source="Reactome">Glucosamine-fructose 6-phosphate aminotransferases 1 and 2 (GFPT1,2) are the first and rate-limiting enzymes in the hexosamine synthesis pathway, and thus formation of hexosamines like N-acetylglucosamine (GlcNAc). These enzymes probably play a role in limiting the availability of substrates for the N- and O-linked glycosylation of proteins. GFPT1 and 2 are required for normal functioning of neuromuscular synaptic transmission. Defects in GFPT1 lead to myasthenia, congenital, with tubular aggregates 1 (CMSTA1; MIM:610542), characterised by altered muscle fibre morphology and impaired neuromuscular junction development. Sufferers of CMSTA1 show a good response to acetylcholinesterase inhibitors (Senderek et al. 2011). The missense mutations observed do not always result in significant reduction in enzyme activity, but biopsies show reduced amounts of GFPT1 protein suggesting increased turnover or defective translation (Senderek et al. 2011).</Comment>
    <BiopaxRef>a16</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="604.0" CenterY="169.5" Width="138.0" Height="61.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4085023" />
  </DataNode>
  <DataNode TextLabel="Defective GALE&#xA;causes EDG" GraphId="e2df0" Type="Pathway">
    <Comment Source="Reactome">Cytosolic UDP-galactose 4'-epimerase (GALE) catalyses the reversible interconversion of UDP-D-galactose (UDP-Gal) and UDP-glucose (UDP-Glc), the third reacton in the Leloir pathway of galactose metabolism. GALE can also catalyse the epimerisation of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The active form of the enzyme is a homodimer with one molecule of bound NAD per monomer (GALE:NAD+ dimer). Defects in GALE can cause Epimerase-deficiency galactosemia (EDG; MIM:230350), or type III galactosemia (diseases of galactose metabolism) whose clinical features include early-onset cataracts, liver damage, deafness and mental retardation. Historically, it was considered that there were two forms of GALE deficidency; a benign ("peripheral") form where there is no GALE activity in red blood cells and characterised by mild symptoms (Gitzelmann 1972) and a rarer "generalised" form with no detectable GALE activity in all tissues resulting in more severe symptoms (Holton et al. 1981). The disease is now considered to be a continuum (Openo et al. 2006).  </Comment>
    <BiopaxRef>cdf</BiopaxRef>
    <BiopaxRef>b8d</BiopaxRef>
    <BiopaxRef>e99</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="288.5" CenterY="68.0" Width="179.0" Height="100.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5609977" />
  </DataNode>
  <DataNode TextLabel="Defective DHDDS&#xA;causes RP59" GraphId="b9d13" Type="Pathway">
    <Comment Source="Reactome">The ER membrane-associated enzyme dehydrodolichyl diphosphate synthase (DHDDS) (Endo et al. 2003) normally mediates the sequential head-to-tail cis addition of multiple isopentyl pyrophosphate (IPP) molecules to farnesyl pyrophosphate (E,E-FPP) to produce polyprenol pyrophosphate (pPPP) (Shridas et al. 2003). Dolichol in humans contain homologues ranging from 17-23 isoprene units, the most common homologues contain 19 or 20 isoprene units (Freeman et al. 1980). Dolichol is an important substrate in the N-glycosylation of proteins, including rhodopsin.&lt;br&gt;&lt;br&gt;Defects in DHDDS cause retinitis pigmentosa 59 (RP59; MIM:613861), a pigment retinopathy, characterised by retinal pigment deposits (visible on fundus examination) and primary loss of rod photoreceptors followed by secondary loss of cone photoreceptors. Sufferers typically have night vision blindness and loss of mid to peripheral vision. As the condition progresses, they lose far peripheral vision and eventually central vision (Zuchner et al. 2011).</Comment>
    <BiopaxRef>fd0</BiopaxRef>
    <BiopaxRef>a58</BiopaxRef>
    <BiopaxRef>e98</BiopaxRef>
    <BiopaxRef>d87</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="102.5" CenterY="169.5" Width="133.0" Height="71.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4755609" />
  </DataNode>
  <DataNode TextLabel="Defective PGM1&#xA;causes PGM1-CDG" GraphId="f1e61" Type="Pathway">
    <Comment Source="Reactome">Phosphoglucomutases 1 and 2 (PGM1, 2) are involved in the cytosolic biosynthesis of nucleotide sugars needed for glycan biosynthesis, specifically, the isomerisation of glucose-6-phosphate (G6P) into glucose-1-phosphate (G1P). Defects in PGM1 can cause congenital disorder of glycosylation 1t (CDG1t, now known as PGM1-CDG; MIM:614921), a broad spectrum disorder characterised by under-glycosylated serum glycoproteins (Timal et al. 2012, Tegtmeyer et al. 2014). CDGs result in a wide variety of clinical features such as defects in nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. </Comment>
    <BiopaxRef>d67</BiopaxRef>
    <BiopaxRef>d1e</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="109.0" CenterY="65.0" Width="146.0" Height="70.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5609974" />
  </DataNode>
  <DataNode TextLabel="Defective PMM2&#xA;causes PMM2-CDG" GraphId="fcf47" Type="Pathway">
    <Comment Source="Reactome">Phosphomannomutase 2 (PMM2) normally catalyses the isomerisation of mannose 6-phosphate (Man6P) to mannose 1-phosphate (Man1P) in the cytosol of cells. Man1P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for critical mannosyl transfer reactions in the N-glycosylation of proteins. Mutations in the PMM2 gene are one of the causes of Jaeken syndrome, a congenital disorder of glycosylation type 1a (PMM2-CDG, previously CDG-1a) (Matthijs et al. 1997). PMM2-CDG was first described in Belgian identical twin sisters, characterized by psychomotor retardation and multiple serum glycoprotein abnormalities. Serum and CSF transferrin were found to be deficient in sialic acid (Jaeken et al. 1984). PMM2-CDG is the most common CDG disease subtype.</Comment>
    <BiopaxRef>a4b</BiopaxRef>
    <BiopaxRef>c67</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="266.0" CenterY="269.5" Width="150.0" Height="73.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4043911" />
  </DataNode>
  <DataNode TextLabel="Defective DOLK&#xA;causes DOLK-CDG" GraphId="a732a" Type="Pathway">
    <Comment Source="Reactome">Dolichol kinase (DOLK, TMEM15) normally mediates the phosphorylation of dolichol (DCHOL) to form dolichyl phosphate (DOLP) in the ER membrane (Fernandez et al. 2002). DOLP is an important substrate in the synthesis of N- and O-glycosylated proteins and GPI anchors. Defects in DOLK cause congenital disorder of glycosylation type 1m (DOLK-CDG, CDG1m, also known as dolichol kinase deficiency; MIM:610768), a severe mutisystem disorder characterised by under-glycosylated serum glycoproteins. This disorder has a very severe phenotype and death can occur in early life (Kranz et al. 2007).</Comment>
    <BiopaxRef>b90</BiopaxRef>
    <BiopaxRef>fcf</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="441.0" CenterY="171.5" Width="142.0" Height="71.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4755583" />
  </DataNode>
  <DataNode TextLabel="Defective DPM1&#xA;causes DPM1-CDG" GraphId="ca3b5" Type="Pathway">
    <Comment Source="Reactome">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM1 can cause congenital disorder of glycosylation 1e (DPM1-CDG, CDG-1e; MIM:608799), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Kim et al. 2000, Imbach et al. 2000, Garcia-Silva et al. 2004).</Comment>
    <BiopaxRef>ba8</BiopaxRef>
    <BiopaxRef>b95</BiopaxRef>
    <BiopaxRef>d48</BiopaxRef>
    <BiopaxRef>c4a</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="441.0" CenterY="266.0" Width="144.0" Height="70.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4717374" />
  </DataNode>
  <DataNode TextLabel="Defective GALT can&#xA;cause GALCT" GraphId="f4fe8" Type="Pathway">
    <Comment Source="Reactome">Galactose-1-phosphate uridylyltransferase (GALT) is one of the enzymes involved in galactose metabolism in the Leloir pathway. GALT catalyses the transfer of uridine monophosphate (UMP) from UDP-glucose (UDP-Glc) to galactose-1-phosphate (Gal1P) to form UDP-galactose (UDP-Gal) and glucose 1-phosphate. Defects in GALT can cause Galactosemia (GALCT; MIM:230400), an autosomal recessive disorder of galactose metabolism presenting in neonatals that causes jaundice, cataracts and mental retardation (Bosch 2006).</Comment>
    <BiopaxRef>c25</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="464.0" CenterY="66.5" Width="142.0" Height="61.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5609978" />
  </DataNode>
  <DataNode TextLabel="Defective DPM2&#xA;causes DPM2-CDG" GraphId="d31a0" Type="Pathway">
    <Comment Source="Reactome">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM2 can cause congenital disorder of glycosylation 1u (DPM2-CDG, CDG1u; MIM:615042), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Barone et al. 2012). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</Comment>
    <BiopaxRef>c4a</BiopaxRef>
    <BiopaxRef>ced</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="610.5" CenterY="265.0" Width="145.0" Height="78.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4719377" />
  </DataNode>
  <DataNode TextLabel="Defective GNE causes&#xA;sialuria, NK and&#xA;IBM2" GraphId="d69bc" Type="Pathway">
    <Comment Source="Reactome">Sialuria (MIM:269921) is caused by a metabolic defect where the UDP?N?acetylglucosamine 2?epimerase, N?acetylmannosamine kinase (GNE) gene lacks feedback inhibition resulting in constitutive overproduction of free sialic acid (Neu5Ac) (Montreuil et al. 1968, Fontaine et al. 1968). Sialuria is characterised by a large cytoplasmic accumulation and urinary excretion of Neu5Ac (Kamerling et al. 1979). Sialurias differ from sialidoses, in which there is storage and excretion of 'bound' Neu5Ac. Defects in GNE also cause Nonaka myopathy (NK; MIM:605820), an early adult-onset disorder characterised by muscle weakness and wasting of distal muscles, especially the anterior tibial muscles (Nonaka et al. 1981, Asaka et al. 2001). Defects in GNE also cause inclusion body myopathy 2 (IBM2; MIM:600737), an autosomal recessive disorder with a similar phenotype to Nonaka myopathy (NK). IBM2 is an adult-onset, proximal and distal muscle weakness and wasting disorder. Muscle biospsy reveals from sufferers shows a rimmed vacuole myopathy and the degenerating muscle fibers contained abnormal amounts of beta-amyloid protein such as that found in neurodegenerative diorders. However, there is no neurological symptoms in these patients (Argov &amp; Yarom 1984).</Comment>
    <BiopaxRef>ac9</BiopaxRef>
    <BiopaxRef>e61</BiopaxRef>
    <BiopaxRef>d8b</BiopaxRef>
    <BiopaxRef>be9</BiopaxRef>
    <BiopaxRef>be4</BiopaxRef>
    <BiopaxRef>f51</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="290.5" CenterY="372.5" Width="159.0" Height="95.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4085011" />
  </DataNode>
  <DataNode TextLabel="Defective DPM3&#xA;causes DPM3-CDG" GraphId="d6df1" Type="Pathway">
    <Comment Source="Reactome">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM3 can cause congenital disorder of glycosylation 1o (DPM3-CDG, CDG1o; MIM:612937), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Lefeber et al. 2009).&lt;br&gt;&lt;br&gt;Four biosynthetic pathways depend on DOLPman; N-glycosylation, O-mannosylation, C-Mannosylation and GPI-anchor biosynthesis. A defect in DPM3 strongly reduces O-mannosylation of alpha-dystroglycan, explaining the clinical phenotype of muscular dystrophy and linking the congenital disorders of glycosylation with the dystroglycanopathies (Lefeber et al. 2009).</Comment>
    <BiopaxRef>c4a</BiopaxRef>
    <BiopaxRef>e1f</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="107.5" CenterY="364.5" Width="141.0" Height="65.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4719360" />
  </DataNode>
  <DataNode TextLabel="Defective MPI causes&#xA;MPI-CDG" GraphId="a8663" Type="Pathway">
    <Comment Source="Reactome">Mannose 6-phosphate isomerase (MPI) normally isomerises fructose 6-phosphate (Fru6P) to mannose 6-phosphate (Man6P) in the cytosol. Man6P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for mannosyl transfer reactions in the N-glycosylation of proteins. Defects in MPI cause congenital disorder of glycosylation 1b (MPI-CDG, previously known as CDG1b,; MIM:602579), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Schollen et al. 2000). Unlike PMM2-CDG (CDG1a), there is no neurological involvement with MPI-CDG. Instead, patients present predominantly with diarrhoea, failure to thrive and protein-losing enteropathy (Pelletier et al. 1986). MPI-CDG is one of two CDGs that can be treated with oral mannose supplementation, but can be fatal if left untreated (Marquardt &amp; Denecke 2003).</Comment>
    <BiopaxRef>a22</BiopaxRef>
    <BiopaxRef>d6c</BiopaxRef>
    <BiopaxRef>e07</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="102.0" CenterY="267.0" Width="130.0" Height="74.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-4043916" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ca4">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17506657</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation: a rapidly expanding disease family.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Jaeken J, Matthijs G.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a59">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25840006</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Neurological aspects of human glycosylation disorders.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Freeze HH, Eklund EA, Ng BG, Patterson MC.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ec6">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12705493</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Clinical features of galactokinase deficiency: a review of the literature.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bosch AM, Bakker HD, van Gennip AH, van Kempen JV, Wanders RJ, Wijburg FA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e11">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">20700148</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Next generation sequencing in a family with autosomal recessive Kahrizi syndrome (OMIM 612713) reveals a homozygous frameshift mutation in SRD5A3.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kahrizi K, Hu CH, Garshasbi M, Abedini SS, Ghadami S, Kariminejad R, Ullmann R, Chen W, Ropers HH, Kuss AW, Najmabadi H, Tzschach A.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bc9">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">20637498</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, De Brouwer AP, Blümel P, Sykut-Cegielska J, Houliston S, Swistun D, Ali BR, Dobyns WB, Babovic-Vuksanovic D, van Bokhoven H, Wevers RA, Raetz CR, Freeze HH, Morava E, Al-Gazali L, Gleeson JG.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="aa2">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22240719</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRD5A3-CDG: a patient with a novel mutation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kasapkara CS, Tümer L, Ezgü FS, Hasanoğlu A, Race V, Matthijs G, Jaeken J.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a16">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21310273</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Senderek J, Müller JS, Dusl M, Strom TM, Guergueltcheva V, Diepolder I, Laval SH, Maxwell S, Cossins J, Krause S, Muelas N, Vilchez JJ, Colomer J, Mallebrera CJ, Nascimento A, Nafissi S, Kariminejad A, Nilipour Y, Bozorgmehr B, Najmabadi H, Rodolico C, Sieb JP, Steinlein OK, Schlotter B, Schoser B, Kirschner J, Herrmann R, Voit T, Oldfors A, Lindbergh C, Urtizberea A, von der Hagen M, Hübner A, Palace J, Bushby K, Straub V, Beeson D, Abicht A, Lochmüller H.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cdf">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">4644860</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Deficiency of uridine diphosphate galactose 4-epimerase in blood cells of an apparently healthy infant. Preliminary communication.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Gitzelmann R.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b8d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">7305435</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Galactosaemia: a new severe variant due to uridine diphosphate galactose-4-epimerase deficiency.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Holton JB, Gillett MG, MacFaul R, Young R.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e99">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16385452</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Epimerase-deficiency galactosemia is not a binary condition.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Openo KK, Schulz JM, Vargas CA, Orton CS, Epstein MP, Schnur RE, Scaglia F, Berry GT, Gottesman GS, Ficicioglu C, Slonim AE, Schroer RJ, Yu C, Rangel VE, Keenan J, Lamance K, Fridovich-Keil JL.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fd0">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">7374371</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Analysis of dolichol in human tissues by high pressure liquid chromatography.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Freeman DJ, Rupar CA, Carroll KK.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a58">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">14652022</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Identification and characterization of a cDNA encoding a long-chain cis-isoprenyltranferase involved in dolichyl monophosphate biosynthesis in the ER of brain cells.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Shridas P, Rush JS, Waechter CJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e98">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21295283</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Whole-exome sequencing links a variant in DHDDS to retinitis pigmentosa.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Züchner S, Dallman J, Wen R, Beecham G, Naj A, Farooq A, Kohli MA, Whitehead PL, Hulme W, Konidari I, Edwards YJ, Cai G, Peter I, Seo D, Buxbaum JD, Haines JL, Blanton S, Young J, Alfonso E, Vance JM, Lam BL, Peričak-Vance MA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d87">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12591616</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Identification of human dehydrodolichyl diphosphate synthase gene.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Endo S, Zhang YW, Takahashi S, Koyama T.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d67">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22492991</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Timal S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J, Paprocka J, Jamroz E, van Spronsen FJ, Körner C, Gilissen C, Rodenburg RJ, Eidhof I, Van den Heuvel L, Thiel C, Wevers RA, Morava E, Veltman J, Lefeber DJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d1e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24499211</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Multiple phenotypes in phosphoglucomutase 1 deficiency.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tegtmeyer LC, Rust S, van Scherpenzeel M, Ng BG, Losfeld ME, Timal S, Raymond K, He P, Ichikawa M, Veltman J, Huijben K, Shin YS, Sharma V, Adamowicz M, Lammens M, Reunert J, Witten A, Schrapers E, Matthijs G, Jaeken J, Rymen D, Stojkovic T, Laforêt P, Petit F, Aumaître O, Czarnowska E, Piraud M, Podskarbi T, Stanley CA, Matalon R, Burda P, Seyyedi S, Debus V, Socha P, Sykut-Cegielska J, van Spronsen F, de Meirleir L, Vajro P, DeClue T, Ficicioglu C, Wada Y, Wevers RA, Vanderschaeghe D, Callewaert N, Fingerhut R, van Schaftingen E, Freeze HH, Morava E, Lefeber DJ, Marquardt T.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a4b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">9140401</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome).</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, Van Schaftingen E.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c67">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">6543331</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Jaeken J, van Eijk HG, van der Heul C, Corbeel L, Eeckels R, Eggermont E.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b90">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17273964</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A defect in dolichol phosphate biosynthesis causes a new inherited disorder with death in early infancy.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kranz C, Jungeblut C, Denecke J, Erlekotte A, Sohlbach C, Debus V, Kehl HG, Harms E, Reith A, Reichel S, Grobe H, Hammersen G, Schwarzer U, Marquardt T.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fcf">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12213788</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Expression and characterization of a human cDNA that complements the temperature-sensitive defect in dolichol kinase activity in the yeast sec59-1 mutant: the enzymatic phosphorylation of dolichol and diacylglycerol are catalyzed by separate CTP-mediated kinase activities in Saccharomyces cerevisiae.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fernandez F, Shridas P, Jiang S, Aebi M, Waechter CJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ba8">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">15669674</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Congenital disorder of glycosylation (CDG) type Ie. A new patient.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">García-Silva MT, Matthijs G, Schollen E, Cabrera JC, Sanchez del Pozo J, Martí Herreros M, Simón R, Maties M, Martín Hernández E, Hennet T, Briones P.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b95">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10642602</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Imbach T, Schenk B, Schollen E, Burda P, Stutz A, Grunewald S, Bailie NM, King MD, Jaeken J, Matthijs G, Berger EG, Aebi M, Hennet T.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d48">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10642597</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie)</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kim S, Westphal V, Srikrishna G, Mehta DP, Peterson S, Filiano J, Karnes PS, Patterson MC, Freeze HH.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c4a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10835346</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human dolichol-phosphate-mannose synthase consists of three subunits, DPM1, DPM2 and DPM3.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Maeda Y, Tanaka S, Hino J, Kangawa K, Kinoshita T.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c25">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16838075</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Classical galactosaemia revisited.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bosch AM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ced">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23109149</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Barone R, Aiello C, Race V, Morava E, Foulquier F, Riemersma M, Passarelli C, Concolino D, Carella M, Santorelli F, Vleugels W, Mercuri E, Garozzo D, Sturiale L, Messina S, Jaeken J, Fiumara A, Wevers RA, Bertini E, Matthijs G, Lefeber DJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ac9">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">5658957</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">[Description of a new type of melituria, called sialuria].</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Montreuil J, Biserte G, Strecker G, Spik G, Fontaine G, Farriaux JP.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e61">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">444571</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2-Acetamidoglucal, a new metabolite isolated from the urine of a patient with sialuria.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kamerling JP, Strecker G, Farriaux JP, Dorland L, Haverkamp J, Vliegenthart JF.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d8b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">5678410</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">[Sialuria: an original metabolic disorder].</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fontaine G, Biserte G, Montreuil J, Dupont A, Farriaux JP.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="be9">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">7252518</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nonaka I, Sunohara N, Ishiura S, Satoyoshi E.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="be4">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11721884</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homozygosity and linkage disequilibrium mapping of autosomal recessive distal myopathy (Nonaka distal myopathy).</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Asaka T, Ikeuchi K, Okino S, Takizawa Y, Satake R, Nitta E, Komai K, Endo K, Higuchi S, Oyake T, Yoshimura T, Suenaga A, Uyama E, Saito T, Konagaya M, Sunohara N, Namba R, Takada H, Honke K, Nishina M, Tanaka H, Shinagawa M, Tanaka K, Matsushima A, Tsuji S, Takamori M.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f51">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">6737002</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">"Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in Iranian Jews.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Argov Z, Yarom R.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e1f">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19576565</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lefeber DJ, Schönberger J, Morava E, Guillard M, Huyben KM, Verrijp K, Grafakou O, Evangeliou A, Preijers FW, Manta P, Yildiz J, Grünewald S, Spilioti M, van den Elzen C, Klein D, Hess D, Ashida H, Hofsteenge J, Maeda Y, van den Heuvel L, Lammens M, Lehle L, Wevers RA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a22">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10980531</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Genomic organization of the human phosphomannose isomerase (MPI) gene and mutation analysis in patients with congenital disorders of glycosylation type Ib (CDG-Ib).</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Schollen E, Dorland L, de Koning TJ, Van Diggelen OP, Huijmans JG, Marquardt T, Babovic-Vuksanovic D, Patterson M, Imtiaz F, Winchester B, Adamowicz M, Pronicka E, Freeze H, Matthijs G.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d6c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">3080572</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Secretory diarrhea with protein-losing enteropathy, enterocolitis cystica superficialis, intestinal lymphangiectasia, and congenital hepatic fibrosis: a new syndrome.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pelletier VA, Galéano N, Brochu P, Morin CL, Weber AM, Roy CC.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e07">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12756558</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Marquardt T, Denecke J.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

